S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Top 5 AI Stocks to Buy for 2024 (Ad)
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
The only accurate crypto trading system I know … (Ad)
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
You won't believe what Citigroup just did to it's depositors (Ad)
Undervalued UnitedHealth Group Won’t Be For Long
PayPal’s User Decline Won’t Stop Its Double-Digit Upside
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Top 5 AI Stocks to Buy for 2024 (Ad)
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
The only accurate crypto trading system I know … (Ad)
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
You won't believe what Citigroup just did to it's depositors (Ad)
Undervalued UnitedHealth Group Won’t Be For Long
PayPal’s User Decline Won’t Stop Its Double-Digit Upside
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Top 5 AI Stocks to Buy for 2024 (Ad)
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
The only accurate crypto trading system I know … (Ad)
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
You won't believe what Citigroup just did to it's depositors (Ad)
Undervalued UnitedHealth Group Won’t Be For Long
PayPal’s User Decline Won’t Stop Its Double-Digit Upside
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Top 5 AI Stocks to Buy for 2024 (Ad)
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
The only accurate crypto trading system I know … (Ad)
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
You won't believe what Citigroup just did to it's depositors (Ad)
Undervalued UnitedHealth Group Won’t Be For Long
PayPal’s User Decline Won’t Stop Its Double-Digit Upside
Free Trial
NASDAQ:GBT

Global Blood Therapeutics (GBT) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)
Free GBT Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$68.49
▼
$68.49
50-Day Range
$68.07
▼
$68.49
52-Week Range
$21.65
▼
$73.02
Volume
74 shs
Average Volume
2.07 million shs
Market Capitalization
$4.62 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
GBT stock logo

About Global Blood Therapeutics Stock (NASDAQ:GBT)

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

GBT Stock News Headlines

March 25, 2024 | skift.com
Amex GBT to Acquire CWT for $570 Million
March 22, 2024 | msn.com
How Dr. Ted Love, a cardiologist turned biotech executive, sold his sickle cell company to Pfizer for $5.4B
April 16, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
February 5, 2024 | forbes.com
How Dr. Ted Love Sold Sickle Cell Company To Pfizer For $5.4 Billion
December 27, 2023 | msn.com
US biotech firm addresses critical gap in blood pressure management
December 20, 2023 | bbc.com
Should we pay people for donating blood?
November 13, 2023 | bizjournals.com
A serial biotech company founder has Parkinson's. His latest company is targeting a potentially game-changing therapy
November 8, 2023 | skift.com
Amex GBT Sees More Small Companies Needing Business Travel Help
April 16, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
November 8, 2023 | finance.yahoo.com
GBT Technologies Cancels and Voids Reverse Stock Split
October 6, 2023 | finance.yahoo.com
Global Peripheral Blood Mononuclear Cells Research Report 2023: R&D Revolution - PBMCs Paving the Way for Medical Breakthroughs
September 28, 2023 | benzinga.com
Diabetes Prevalence Continues To Rise – Better Therapeutics' Digital Treatment Could Help Change This Trajectory
July 28, 2023 | finance.yahoo.com
PFE Mar 2024 32.500 call
June 17, 2023 | benzinga.com
Gout Therapeutics Market Challenges, Drivers, Growth Opportunities, and Major Company Profiles 2023
June 14, 2023 | finance.yahoo.com
Global Patient Blood Management Market to Reach $23.6 Billion by 2030
June 12, 2023 | finance.yahoo.com
Global Lymphoma Therapeutics Market Report 2023: Sector is Expected to Reach $24.9 Billion by 2029 at a CAGR of 7.8%
June 11, 2023 | finance.yahoo.com
Global Health Study Validates Biospectal OptiBP Mobile Blood Pressure Measurement App Accuracy Across Diverse Settings
June 7, 2023 | bizjournals.com
Ted Love, now the chair of biotech's big trade group, talks drug access, leadership and 'crazy' co-pays
June 6, 2023 | finance.yahoo.com
GBT Received a Notice of Allowance for its Microchip Reliability Verification and Auto-Correction Patent Application
June 4, 2023 | es-us.finanzas.yahoo.com
The Global Non-insulin Diabetes Therapeutics Market
May 23, 2023 | msn.com
Pfizer Announces $5.4 Billion Deal to Acquire Global Blood Therapeutics
May 17, 2023 | marketwatch.com
(2023-2030) Anemia Drugs Market Size, Share and Trend Analysis Report, Worldwide Opportunities, Demand Forecast
May 11, 2023 | marketwatch.com
Artificial Blood Market, Global Outlook and Forecast 2023-2029
May 5, 2023 | marketwatch.com
2030 Blood Cancer Therapeutics Market Forecast: Positive Growth Trajectory Ahead
May 5, 2023 | finance.yahoo.com
Rare Disease Therapeutics Global Market Report 2023: Increasing Number of Patients with Rare Diseases Bolsters Growth
May 5, 2023 | finance.yahoo.com
Monoclonal Antibody Therapeutics Market to Surpass US$ 534.26 Billion by 2030, Says Coherent Market Insights (CMI)
May 5, 2023 | marketwatch.com
Metabolic Disorder Therapeutics Market 2023 Set to Growth Highest CAGR and Revenue by 2030
See More Headlines
Receive GBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Global Blood Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
4/16/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GBT
CUSIP
N/A
CIK
1629137
Web
www.gbt.com
Phone
(650) 741-7700
Fax
N/A
Employees
457
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($5.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-303,090,000.00
Net Margins
-137.30%
Pretax Margin
-137.01%
Return on Equity
-170.37%
Return on Assets
-39.24%

Debt

Debt-to-Equity Ratio
4.92
Current Ratio
6.88
Quick Ratio
6.17

Sales & Book Value

Annual Sales
$194.75 million
Price / Sales
23.73
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.05 per share
Price / Book
22.46

Miscellaneous

Outstanding Shares
67,476,000
Free Float
64,170,000
Market Cap
$4.62 billion
Optionable
Optionable
Beta
0.45
20 Stocks to Sell Now Cover
20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Ted W. Love M.D. (Age 63)
    Pres, CEO & Director
    Comp: $1.06M
  • Mr. Jeffrey S. Farrow (Age 60)
    CFO & Principal Accounting Officer
    Comp: $672.67k
  • Ms. Jung E. Choi (Age 52)
    Chief Bus. & Strategy Officer
    Comp: $645k
  • Mr. David L. Johnson (Age 53)
    Chief Commercial Officer
    Comp: $661.5k
  • Dr. Kim Smith-Whitley M.D. (Age 61)
    Exec. VP and Head of R&D
    Comp: $654k
  • Dr. David R. Phillips
    Founder & Advisor
  • Dr. Matthew P. Jacobson Ph.D.
    Founder & Advisor
  • Dr. Andrej Sali Ph.D.
    Founder & Advisor
  • Ms. Nazila Habibizad (Age 59)
    Exec. VP of Operations
  • Stephanie Yao
    Sr. Director of Corp. Communications & Investor Relations

Key Competitors

View All Competitors

GBT Stock Analysis - Frequently Asked Questions

How were Global Blood Therapeutics' earnings last quarter?

Global Blood Therapeutics, Inc. (NASDAQ:GBT) issued its quarterly earnings results on Thursday, November, 4th. The company reported ($1.13) earnings per share for the quarter, missing analysts' consensus estimates of ($1.10) by $0.03. The company earned $52.05 million during the quarter, compared to analyst estimates of $53.69 million. Global Blood Therapeutics had a negative net margin of 137.30% and a negative trailing twelve-month return on equity of 170.37%. The business's revenue for the quarter was up 41.1% on a year-over-year basis. During the same period in the prior year, the business earned ($0.97) EPS.

What is Ted W. Love, M.D.'s approval rating as Global Blood Therapeutics' CEO?

20 employees have rated Global Blood Therapeutics Chief Executive Officer Ted W. Love, M.D. on Glassdoor.com. Ted W. Love, M.D. has an approval rating of 100% among the company's employees. This puts Ted W. Love, M.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 90.0% of employees surveyed would recommend working at Global Blood Therapeutics to a friend.

What other stocks do shareholders of Global Blood Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Global Blood Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and Block (SQ).

When did Global Blood Therapeutics IPO?

Global Blood Therapeutics (GBT) raised $102 million in an initial public offering (IPO) on Wednesday, August 12th 2015. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

This page (NASDAQ:GBT) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners
Can't believe it's happening again
Manward Press
He Is Giving Away Bitcoin
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
The “Perfect Storm” for Gold
Gold Safe Exchange
1970’s computer coder issues shocking A.I. warning
TradeSmith
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
You won't believe what Citigroup just did to it's depositors
American Alternative
Options trading has suddenly become more reliable.
Eagle Publishing